ANSELL LIMITED (ANN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ANN - ANSELL LIMITED

Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.87
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Ansell is an Australian manufacturer of protective industrial equipment and household and medical gloves. It is the remnant of Pacific Dunlop, once a mighty conglomerate that listed in 1985. The name was changed to Ansell in 2002.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$24.71

27 Mar
2024

0.310

OPEN

$24.12

1.27%

HIGH

$24.77

245,489

LOW

$24.29

TARGET
$25.484 3.1% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
AIM . ASB . CUP . DGL . KPG . QHL . RDX . SRV .
FNARENA'S MARKET CONSENSUS FORECASTS
ANN: 1
Title FY24
Forecast
FY25
Forecast
EPS (cps) 144.2 xxx
DPS (cps) 60.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 17.0 xxx
Dividend Yield 2.4% xxx
Div Pay Ratio(%) 41.6% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.80%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.87

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 26/02 - ex-div 25.21c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx174.6
DPS All xxxxxxxxxxxxxxx69.5
Sales/Revenue xxxxxxxxxxxxxxx2,460.6 M
Book Value Per Share xxxxxxxxxxxxxxx1,908.5
Net Operating Cash Flow xxxxxxxxxxxxxxx243.5 M
Net Profit Margin xxxxxxxxxxxxxxx8.96 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx9.49 %
Return on Invested Capital xxxxxxxxxxxxxxx7.48 %
Return on Assets xxxxxxxxxxxxxxx5.92 %
Return on Equity xxxxxxxxxxxxxxx9.49 %
Return on Total Capital xxxxxxxxxxxxxxx9.66 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx50.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx176 M
Long Term Debt xxxxxxxxxxxxxxx566 M
Total Debt xxxxxxxxxxxxxxx743 M
Goodwill - Gross xxxxxxxxxxxxxxx1,481 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx239 M
Price To Book Value xxxxxxxxxxxxxxx1.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx99.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.06 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,551 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx613 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx18 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

21/02/2024

3

Neutral

$26.00

5.22%

Upon further analysis of yesterday's H1 release, Citi notes the 'miss' was caused by weaker-than-projected revenue and margin for the healthcare division.

Management has narrowed guidance for FY24 and expressed its view that destocking should end in H2, which should allow this divison to start growing again.

All in all, amendments to future estimates remain rather benign (though positive). Citi's price target remains at $26. Neutral.

FORECAST
Citi forecasts a full year FY24 dividend of 57.01 cents and EPS of 143.36 cents.
Citi forecasts a full year FY25 dividend of 69.93 cents and EPS of 172.54 cents.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

ANN STOCK CHART